Top news of the day from across the health care landscape.
The FDA has granted priority review to AstraZeneca and Daiichi Sankyo for trastuzumab deruxtecan (DS-8201) for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer, AstraZeneca reported. According to the press release, the Biologics License Application is based on the combination of data from a phase 1 trial and the phase 2 DESTINY-Breast01 trial, which validated the response rate observed in the previous trial. The Prescription Drug User Fee Act date for trastuzumab deruxtecan is set for the second quarter of 2020, AstraZeneca said.
A new study showed that vedolizumab can help induce endoscopic and histologic remission in patients with Crohn disease, MD Magazine reported. According to the article, the study included 110 patients with active Crohn disease who received 300 mg of open-label vedolizumab infusions at weeks 0, 2, and 6, and every 8 weeks after through a 52-week program. Overall, the data indicated that approximately one-third of patients with Crohn disease achieved endoscopic remission after 52 weeks of treatment with vedolizumab and two-thirds achieved histologic remission at week 26, the article reported.
A recent research review suggests that women who use intrauterine devices (IUDs) for birth control may be less likely to develop ovarian cancer, Reuters reported. According to the article, the researchers examined data from 11 previous studies that tracked individual-level information on IUD use and ovarian cancer diagnosis for several hundred thousand women. Overall, women who used IUDs were 32% less likely than other women to develop ovarian cancer, the article reported.